Vivos Therapeutics, Inc. (VVOS): Nasdaq/NYSE listing notice — Vivos Therapeutics gets Nasdaq delisting notice for negative equity of $1.55M

Vivos Therapeutics, Inc.

Negative stockholders' equity of ~$1.55M as of Dec 31, 2025, below Nasdaq's $2.5M minimum requirement.
Nasdaq letter received April 17, 2026; Company must submit compliance plan by June 1, 2026.
Raised $6.8M in Q1 2026: $4.6M warrant exercise inducement + $2.25M private placement with existing investor.
If plan accepted, Nasdaq may grant extension to Oct 14, 2026; failure to regain compliance risks delisting.
No immediate impact on common stock listing; Company intends to submit plan timely.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 17, 2026, Vivos Therapeutics, Inc. (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholde

View on SEC.gov

Browse all listing & compliance notices →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-018562

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.